Amyris, Inc. (NASDAQ:AMRS - Get Rating) Director Frank Kung sold 200,000 shares of the stock in a transaction that occurred on Wednesday, September 21st. The shares were sold at an average price of $3.50, for a total transaction of $700,000.00. Following the completion of the sale, the director now directly owns 80,000 shares of the company's stock, valued at approximately $280,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Frank Kung also recently made the following trade(s):
- On Monday, September 19th, Frank Kung sold 1,080,676 shares of Amyris stock. The shares were sold at an average price of $3.80, for a total transaction of $4,106,568.80.
- On Thursday, September 15th, Frank Kung sold 1,385,000 shares of Amyris stock. The shares were sold at an average price of $4.20, for a total transaction of $5,817,000.00.
Amyris Stock Down 4.7 %
Shares of AMRS stock traded down $0.16 during mid-day trading on Thursday, reaching $3.22. 4,678,658 shares of the company were exchanged, compared to its average volume of 6,480,745. Amyris, Inc. has a fifty-two week low of $1.47 and a fifty-two week high of $15.12. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.13 and a current ratio of 1.66. The company has a market capitalization of $1.04 billion, a P/E ratio of -2.13 and a beta of 1.36. The business's 50 day simple moving average is $2.81 and its 200 day simple moving average is $3.03.
Amyris (NASDAQ:AMRS - Get Rating) last released its quarterly earnings results on Tuesday, August 9th. The biotechnology company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.06). The firm had revenue of $65.20 million for the quarter, compared to analyst estimates of $81.53 million. During the same period in the prior year, the firm earned ($0.16) earnings per share. The company's quarterly revenue was up 24.7% on a year-over-year basis. Research analysts predict that Amyris, Inc. will post -1.11 earnings per share for the current year.
Wall Street Analysts Forecast Growth
AMRS has been the subject of several recent research reports. Roth Capital downgraded shares of Amyris from a "buy" rating to a "neutral" rating in a research report on Wednesday, August 10th. JPMorgan Chase & Co. initiated coverage on shares of Amyris in a research report on Friday, June 24th. They issued a "neutral" rating for the company. Finally, Piper Sandler increased their price objective on shares of Amyris from $2.50 to $4.00 and gave the company a "neutral" rating in a research report on Monday.
Institutional Trading of Amyris
Hedge funds have recently made changes to their positions in the stock. Farallon Capital Management LLC lifted its stake in Amyris by 55.9% during the first quarter. Farallon Capital Management LLC now owns 16,931,427 shares of the biotechnology company's stock worth $73,821,000 after purchasing an additional 6,071,616 shares during the last quarter. Edmond DE Rothschild Holding S.A. lifted its stake in Amyris by 52.6% during the second quarter. Edmond DE Rothschild Holding S.A. now owns 6,965,700 shares of the biotechnology company's stock worth $12,887,000 after purchasing an additional 2,401,900 shares during the last quarter. State of Michigan Retirement System lifted its stake in Amyris by 92.2% during the first quarter. State of Michigan Retirement System now owns 4,815,000 shares of the biotechnology company's stock worth $20,993,000 after purchasing an additional 2,310,000 shares during the last quarter. Bank of Montreal Can bought a new position in Amyris during the fourth quarter worth $8,443,000. Finally, Laurion Capital Management LP bought a new position in Amyris during the fourth quarter worth $6,704,000. Institutional investors and hedge funds own 43.08% of the company's stock.
About Amyris
(
Get Rating)
Amyris, Inc, a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Amyris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amyris wasn't on the list.
While Amyris currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
